A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Velpatasvir and Sofosbuvir (Epclusa)

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2016-06-28
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$278.16/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$572.69
Across all dosage forms in distribution.
Highest NADAC
$867.22
Range is tight.
Plans with PA
717 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Velpatasvir and Sofosbuvir used for?

Velpatasvir and Sofosbuvir is a Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Velpatasvir and Sofosbuvir?

No. Velpatasvir and Sofosbuvir is brand-only with no generic equivalents currently in market.

How much does my plan pay for Velpatasvir and Sofosbuvir?

Across 329 Part D plans, Velpatasvir and Sofosbuvir averages $572.69/unit (NADAC). Lowest available: $278.16/unit. Highest in distribution: $867.22/unit.

Is Velpatasvir and Sofosbuvir on the FDA shortage list?

No. Velpatasvir and Sofosbuvir is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor2 alternatives in D1
01
Sofosbuvir
Brand: Sovaldi
Lowest NADAC
0Generic mfrs
$3.1MCY24 Part D spend
Compare →
02
Sofosbuvir, Velpatasvir, and Voxilaprevir
Brand: Vosevi
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.